|Assessment Status||Rapid Review complete|
|Indication||Prevention of vitamin D deficiency in adult patients with an identified risk, initial treatment of clinically relevant vitamin D deficiency, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.|
|Rapid review commissioned||11/05/2022|
|Rapid review completed||23/06/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that Egostar® not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.